

***A Virtual Reality View — Evolving Standards of Care in Psoriasis:
The Influence of Biologics on PASI Goals, Quality of Life, and Special Populations***

TOOLKIT

Articles and Websites

Resource	Web Address
CDC. Psoriasis.	https://www.cdc.gov/psoriasis/index.htm
NIH. MedLinePlus. Psoriasis.	https://medlineplus.gov/psoriasis.html
NIH. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Psoriasis.	https://www.niams.nih.gov/health-topics/psoriasis
Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. (Takeshita J, et al. <i>J Invest Dermatol.</i> 2019;139(8):1672-1679.e1)	https://www.ncbi.nlm.nih.gov/pubmed/30738054
Health Care Utilization for Psoriasis in the United States Differs by Race: An Analysis of the 2001-2013 Medical Expenditure Panel Surveys. (Fischer AH, et al. <i>J Am Acad Dermatol.</i> 2018;78(1):200-203)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035870/
Association of Demographic and Socioeconomic Characteristics With Differences in Use of Outpatient Dermatology Services in the United States. (Tripathi R, et al. <i>JAMA Dermatol.</i> 2018;154(11):1286-1291)	https://www.ncbi.nlm.nih.gov/pubmed/30267073
Stigmatizing Attitudes Toward Persons with Psoriasis Among Laypersons and Medical Students. (Pearl RL, et al. <i>J Am Acad Dermatol.</i> 2019;80(6):1556-1563)	https://www.ncbi.nlm.nih.gov/pubmed/30171876

Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.
(Kaufman BP, Alexis AF. *Am J Clin Dermatol*. 2018;19:405–423)

<https://www.ncbi.nlm.nih.gov/pubmed/29209945>

Selected Ongoing Clinical Trials

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up with Their Providers
NCT03964168

<https://clinicaltrials.gov/ct2/show/NCT03964168?term=biologic&cond=psoriasis&rank=6>

A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
NCT03465696

<https://clinicaltrials.gov/ct2/show/NCT03465696?term=biologic&recrs=abd&cond=psoriasis&rank=10>

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants with Moderate to Severe Plaque Psoriasis (IXORA-R)
NCT03573323

<https://clinicaltrials.gov/ct2/show/NCT03573323?term=biologic&recrs=abd&cond=psoriasis&draw=2&rank=11>

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
NCT03047395

<https://clinicaltrials.gov/ct2/show/NCT03047395?term=biologic&recrs=abd&cond=psoriasis&draw=4&rank=28>

Multi-Dose Study of SHR-1314 in Subjects with Moderate to Severe Plaque Psoriasis
NCT03463187

<https://clinicaltrials.gov/ct2/show/NCT03463187?term=biologic&recrs=abd&cond=psoriasis&draw=6&rank=41>

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients with New-Onset, Moderate to Severe Plaque Psoriasis (STEPin)
NCT03020199

<https://clinicaltrials.gov/ct2/show/NCT03020199?term=biologic&recrs=abd&cond=psoriasis&draw=2&rank=53>

Resources for Patients

American Academy of Dermatology Resource Center	https://www.aad.org/public/diseases/scaly-skin/psoriasis
National Psoriasis Foundation	https://www.psoriasis.org/
National Psoriasis Foundation. Moderate to Severe Psoriasis and Psoriatic Arthritis: Biologic Drugs.	https://www.psoriasis.org/about-psoriasis/treatments/biologics
Skin of Color Society Education Videos	http://skinofcolorsociety.org/dermatology-resources/education-videos/